From Name:
From Email:
To Name:
To Email:

Optional Message:


New cancer biomarker tests stunted by 'vicious cycle'

from Medscape Medical News

Cancer biomarker test development and adoption has "lagged far behind" recent advances in cancer therapies, according to a commentary published in the July 31 issue of Science Translational Medicine. "Despite prodigious advances in tumor biology research, few tumor biomarker tests have been adopted as standard clinical practice," write the authors, a blue ribbon panel of representatives from industry, academia, and professional organizations led by Daniel Hayes, MD, clinical director of the breast oncology program at the University of Michigan Comprehensive Cancer Center in Ann Arbor. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063